Association Between Atopic Dermatitis and Autoimmune Diseases Association Between Atopic Dermatitis and Autoimmune Diseases
This large population-based study explored the association between atopic dermatitis and a wide spectrum of autoimmune diseases. Which autoimmune disorders had the strongest association?The British Journal of Dermatology
Conclusion: Cutaneous ADR patterns and the drugs causing various reactions are changing every year, which may be because of the introduction of newer molecules and changing trends in the use of drugs. In our study, a significant relation of CADRs with autoimmune diseases (P value = 0.004) was also observed.
CONCLUSIONS: The use of anti-herpes treatment when initiating a JAK inhibitor for atopic dermatitis may be prudent, as the costs and risks of prophylactic treatment are low and may be valuable for preventing eczema herpeticum.PMID:34493136 | DOI:10.1080/09546634.2021.1978665
Alopecia areata (AA) is an autoimmune disease resulting in non-scarring hair loss with an estimated lifetime incidence to be 2.1% in the USA for 20 years (1990 –2009) . Although non-life-threatening, AA significantly reduces the life quality of patients compared with psoriasis or atopic dermatitis [2,3].
CONCLUSIONS: Although the role of RCM and OCT has yet to be defined in clinical practice, non-invasive skin imaging shows promising results on inflammatory and autoimmune skin diseases, due to the correlation with histopathologic features.PMID:34423852 | DOI:10.1111/ajd.13695
Cutaneous Lupus Erythematosus (CLE) is a spectrum of autoimmune connective tissue diseases that are characterized histopathologically by interface dermatitis and lupus band reaction. Current treatment options for CLE are based on SLE treatments and include topical steroids, antimalarials, and other immunosuppressants. Many CLE patients exhibit flares which can be triggered by environmental stimuli such as UV light. Tissue-resident memory T cells (Trm) mediate flares in autoimmune skin disorders, though their specificities, functional molecules, and survival factors in CLE have not yet been described.
We present a patient treated with tofacitinib, 5mg twice daily, an oral JAK1/3 inhibitor, who demonstrated clinical improvement of DH and control of new lesion development.PMID:34391330 | DOI:10.5070/D327754365